Learn More
PURPOSE To evaluate the efficacy of cetuximab plus taxane/carboplatin (TC) as first-line treatment of advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS This multicenter, open-label,(More)
3516 Background: Bevacizumab [Avastin (BV)] is a recombinant, humanized monoclonal antibody directed against vascular endothelial growth factor. As presented at ASCO 2003, the addition of BV to IFL(More)
8016 Background: The combination of rituximab plus CHOP chemotherapy (R-CHOP) is widely used as standard of care for DLBCL; however, long-term survival is low in patients (pts) with high (IPI) risk(More)